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Abstract
Hypopituitarism is deficiency of one or more pituitary hormones, of which adrenocorticotrophic hormone (ACTH)
deficiency is the most serious and potentially life-threatening. It may occur in isolation or, more commonly as part
of more widespread pituitary failure. Diagnosis requires demonstration of subnormal cortisol rise in response to
stimulation with hypoglycemia, glucagon, ACTH(1-24) or in the setting of acute illness. The choice of diagnostic
test should be individualised for the patient and clinical scenario. A random cortisol and ACTH level may be
adequate in making a diagnosis in an acutely ill patient with a suspected adrenal crisis e.g. pituitary apoplexy.
Often however, dynamic assessment of cortisol reserve is needed. The cortisol response is both stimulus and
assay- dependent and normative values should be derived locally. Results must be interpreted within clinical
context and with understanding of potential pitfalls of the test used.
Background
Hypopituitarism is a clinical syndrome of deficiencies in
one or more pituitary hormones of which adrenocortico-
trophic hormone (ACTH) deficiency resulting in adrenal
failure is the most serious and potentially life-threatening
feature. ACTH deficiency can present as a part of
generalized pituitary failure (multiple pituitary hormone
deficiency, MPHD) or less commonly as an isolated entity.
In the most severe cases, it can manifest acutely and
dramatically as a life-threatening adrenal crisis with vas-
cular collapse especially during an intercurrent illness
while in other cases, the features are more subtle and
the onset is gradual. It may also be diagnosed during
assessment of pituitary axes as part of routine practice
in those with pituitary tumours or following pituitary
surgery or radiation therapy in otherwise well patients
with little or no symptoms.
Physiology
ACTH is a 39 amino acid peptide produced in the ante-
rior pituitary by proteolytic cleavage of the much larger
precursor polypeptide proopiomelanocortin (POMC).
POMC gene expression, processing to ACTH and ACTH
secretion are stimulated by corticotropin releasing factor
(CRF) which is secreted in the hypothalamus [1]. These
processes are under negative feedback by glucocorticoids.
ACTH secretion can be suppressed by exogenous gluco-
corticoids via this negative feedback mechanism and this
represents the most common cause of ACTH deficiency.
ACTH acts on the G protein coupled melanocortin 2
receptor in the zona fasiculata of the adrenal cortex to
stimulate the synthesis of cortisol. In addition to this
rapid effect, ACTH induces steroidogenic gene trans-
cription and causes adrenal hypertrophy leading to an
increase in the long-term capacity of the adrenal gland
to generate cortisol [2]. This results in the adrenal
hypertrophy seen in chronic ACTH excess. In contrast,
in chronic ACTH deficiency adrenal atrophy can occur.
Cortisol circulates in the blood bound to cortisol binding
globulin (CBG) and free cortisol binds to the glucocorti-
coid receptor in target tissues to regulate gene transcrip-
tion as well as exerting rapid, non-genomic effects [1, 3].
ACTH also stimulates the production of adrenal
androgens, primarily dehydroepiandrosterone (DHEA),
from the zona reticularis. These represent the main
source of circulating androgen in females. Mineralocor-
ticoid production is spared in central hypoadrenalism as
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mineralocorticoid secretion is primarily mediated by the
renin-angiotensin system [4].
Clinical context
ACTH deficiency can be congenital or acquired due to
structural or functional diseases of the pituitary or hypo-
thalamus. It can occur in isolation or as part of more
widespread pituitary failure. The most common cause of
ACTH deficiency is ACTH suppression and subsequent
adrenal atrophy due to chronic glucocorticoid use. Other
causes are outlined in Table 1.
Interrogation of the hypothalamic pituitary axis may
be required acutely or in a more routine setting. The
clinical scenario can mandate which test is performed.
For example a random cortisol and ACTH level may be
adequate in making a diagnosis in an acutely ill patient
with a suspected adrenal crisis e.g. pituitary apoplexy. In
other situations a low morning cortisol level in an at risk
patient may also be sufficient in diagnosing ACTH/corti-
sol deficiency. Often however, dynamic assessment of
cortisol reserves is needed (see below).
In hypopituitarism, there is generally a specific se-
quential failure of pituitary hormones with GH being the
most common pituitary hormone affected followed by
gonadotrophins and culminating in loss of ACTH and
thyroid stimulating hormone (TSH) [5]. ACTH however
can be the first or only pituitary hormone affected in
certain situations such as lymphocytic hypophysitis [6]
or suppression of the hypothalamic-pituitary-adrenal
(HPA) axis by exogenous glucocorticoids.
Detection and treatment of central hypoadrenalism is
important as it has been shown to be associated with in-
creased morbidity and mortality [7, 8].
Testing for central hypoadrenalism
Interrogation of the HPA axis is performed as part of a
formal screening process for hypopituitarism in patients
with organic hypothalamic-pituitary disease such as those
with sellar/parasellar tumours, post pituitary surgery or
apoplexy, history of cranial irradiation or traumatic brain
injury. In other situations the assessment may be triggered
by suggestive symptoms such as fatigue, unexplained
weight loss, spontaneous hypoglycaemia or hyponatraemia.
Timing of assessment
ACTH suppression from exogenous steroids
ACTH suppression and subsequent cortisol deficiency
can result from chronic glucocorticoid use, can be un-
predictable regardless of dose and duration of gluco-
corticoid and recovery can take weeks to years [4, 9].
Patients on long-term glucocorticoids for inflammatory
conditions are frequently referred to specialist endocrine
services for assessment of possible ACTH suppression.
As prednisone can cross-react with the cortisol assay we
suggest waiting until the patient is tapered to a dose of
5 mg at which point they are switched to an equivalent
dose hydrocortisone 10 mg twice daily and a dynamic
test can be carried out with the dose held the afternoon
before and morning of the test.
Pituitary surgery/apoplexy
All patients with sellar/parasellar tumours should be
subjected to an assessment of HPA axis function, with
perhaps the exception of those with pituitary microadeno-
mas who are at a very low risk of ACTH deficiency. Pa-
tients should undergo post-operative interrogation of the
HPA axis regardless of whether they had pre-operative
Table 1 Causes of central hypoadrenalism
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ACTH deficiency as there is potential for these patients to
gain functional recovery providing that viable normal pitu-
itary tissue remains in situ [10].
ACTH deficiency is the most common deficit observed
in pituitary apoplexy occurring in 50–80 % of cases [11].
Due to its high frequency and potentially life-threatening
effects, empiric parenteral corticosteroid is administered,
when possible preceeded by blood drawing for serum
cortisol levels. Pituitary function can recover following
surgical decompression [12, 13]. Therefore post-operative
re-assessment of the HPA axis is required.
A 08.00 h plasma cortisol can be measured on day
1–3 post-operatively in patients not treated with
glucocorticoids and day 3–5 in patients covered with
glucocorticoids once the dose is tapered down to
physiological replacement [14] with the second dose of
hydrocortisone given early in the afternoon (if hydro-
cortisone is used) and the morning dose of hydrocorti-
sone not given until after the sample is drawn. However,
there are conflicting opinions regarding what consti-
tutes a safe level of 08.00 h plasma cortisol [15–17]. Pa-
tients with a 08.00 h unstressed cortisol of >400 nmol/
L have an extremely low risk of ACTH deficiency and
no further dynamic testing of the HPA axis is required
[18, 19]. Conversely, patients with a post-operative
08.00 h cortisol of <100 nmol/L are invariably ACTH
deficient and glucocorticoid replacement should be
commenced. Patients with a 08.00 h cortisol between
these values require definitive testing [17].
The alternative, and our preferred, approach is to
routinely perform a dynamic test of HPA axis function
6–8 weeks post-operatively. This has the advantage of
facilitating early discharge of patients post-operatively
on empiric glucocorticoid replacement rather than wait-
ing for day 3–5 cortisol values and may better identify
those patients with later recovery of cortisol secretion.
Traumatic brain injury
Hypopituitarism is a common occurrence among
survivors of severe or moderate traumatic brain injury
(TBI) with an estimated prevalence of 11–35 %
among adult long term survivors [20]. Acute post TBI
central hypoadrenalism is potentially life-threatening
[21] and has shown to be associated with increased
mortality [7]. In the acute post-traumatic phase
morning cortisol measurements should be carried out
on those with moderate (GCS 9-12) or severe TBI
(GCS ≤ 8) or those with clinical features suggestive of
ACTH deficiency ie. hypotension, hypoglycaemia or
hyponatraemia. Patients should also be tested in the post-
acute phase between 3–6 months after the event as early
abnormalities can recover while new deficiencies may
become apparent later [22].
Post cranial radiation
Hypopituitarism is a recognised consequence of cranial
radiation both for pituitary and non-pituitary brain tu-
mours. Its onset is dose and time dependent. The HPA
axis seems to be the most radio-resistant site in patients
who have undergone irradiation for non-pituitary disor-
ders. Clinically apparent ACTH deficiency is uncommon
(3 %) in patients receiving a total radiation dose of less
than 50Gy to the hypothalamic-pituitary (HP) axis. The
incidence dramatically increases in those receiving more
intensive radiotherapy [23, 24] and is highest in those re-
ceiving pituitary radiotherapy for pituitary tumors [25].
It is our practice to routinely screen patients from 1 year
post cranial radiation and annually thereafter unless a
diagnosis of ACTH deficiency is made.
Choice of test
The choice of the most appropriate test for the assess-
ment of alterations in the HPA axis remains an area of
considerable debate. The “ideal test” is one which is con-
venient, non-expensive, without side-effects while having
a high degree of reproducibility and diagnostic sensitivity
and specificity. Morning cortisol may be useful if it is
clearly low or clearly healthy. In the appropriate clinical
context, an early morning cortisol less than 100 nmol/L
suggests a requirement for glucocorticoid replacement,
while a level greater than 390–400 nmol/L strongly sug-
gests an intact HPA axis [26, 27]. Most patients however re-
quire a dynamic assessment of the HPA axis (see Table 2).
Insulin tolerance test
The insulin tolerance test (ITT) is regarded by many en-
docrinologists as the gold standard for interrogation of
the hypothalamic pituitary axis. Hypoglycemic stress is a
major stimulant of the HPA axis. In a seminal study in
1969, Plumpton and Besser showed that a normal corti-
sol response to ITT predicts an appropriate cortisol
response during major surgery in both healthy and
corticosteroid-treated patients [28]. Therefore normal
response to ITT is highly reassuring (Fig. 1).
The ITT is performed under supervision by intrave-
nous injection of 0.15 units/kg (0.1 units/kg if high sus-
picion of hypocortisolism, 0.2units/kg in insulin resistant
states such as diabetes mellitus or acromegaly) soluble
insulin with measurement of plasma cortisol at 0, 30, 45,
60, 90 and 120 min. Adequate hypoglycemia (blood glu-
cose <2.2 mmol/L) with symptoms must be achieved to
validate the test. The test has the advantage of also ro-
bustly assessing growth hormone (GH) production [29].
Contraindications to the ITT include history of seizures
(particularly relevant in assessment of patients post TBI,
subarachnoid haemorrhage (SAH) or with structural
brain abnormalities who may have increased risk of
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seizures) and ischaemic heart disease (baseline ECG is
required before performing test).
Some advocate against using the ITT in patients with
a baseline cortisol of <100 nmol/L. However, Finucane
et al showed the ITT to be safe in these patients and
also an important diagnostic tool as 4 of 14 patients who
had morning serum cortisol concentrations <100 nmol/L
passed the ITT and remained well during long-term
follow-up without glucocorticoid replacement [26]. Some
centres recommend against the use of ITT in patients
over age of 65 years due to safety concerns but in the pre-
vious paper none of the 9 % of patients who were over
the age of 65 years had any adverse reactions to the test
and we therefore do not use age as a contraindication to
ITT in otherwise healthy individuals as long as the other
exclusion criteria are taken into account.
Glucagon stimulation test
The glucagon stimulation test (GST) can be used to as-
sess both the HPA and GH axes if the ITT is contraindi-
cated, for example in those with heart disease. However
the test is not usually used for the sole assessment of the
HPA axis if GH assessment is not needed. Because of
the false positive results, confirmatory tests (see
below) are needed if the result is abnormal. 1 mg of
glucagon (1.5 mg in those over 100 kgs) is given
intramuscularly and samples taken for glucose, corti-
sol and GH at 0, 90, 120, 150 and 180 min. While
the test is generally safe, up to 30 % of patients re-
port nausea and occasional vomiting [30, 31]. Gluca-
gon induced cortisol release has been shown to be
ACTH dependent [32] but the precise mechanism of
this physiological effect is not well-defined.
Short Synacthen (SST, corticotrophin)Test
Originally introduced to assess cortisol reserve in sus-
pected primary adrenal failure (Addison’s disease), this
test has also gained favour among many endocrinologists
for the indirect assessment of the HPA axis [33–37]
in cases of suspected secondary hypoadrenalism. Its
diagnostic value relies on the assumption that chronic
ACTH deficiency results in adrenal atrophy and therefore
diminished response to exogenous acute ACTH stimu-
lation [38]. The SST should not be used to assess for
central hypoadrenalism therefore for at least 4–6 weeks
post pituitary insult (e.g. surgery or apoplexy).
The high dose SST (HDSST) test involves the intra-
venous or intramuscular administration of 250 mcg of
Synacthen (cosyntropin, ACTH (1-24)) a truncated
ACTH peptide that has full biological activity but longer
half-life than native ACTH (1-39). Baseline morning
serum cortisol and ACTH (if central aetiology of the
suspected hypoadrenalism is not clear) are taken and
then cortisol measurement repeated 30 min after ACTH
is administered. Another variant of the test is the admi-
nistration of low dose (1 mcg) ACTH instead aiming for
better sensitivity but comparing the performances of the
two doses showed them to be equivalent [39]. Further-
more 1 mcg ACTH preparations are not available hence
most centres use the high dose test.
Fig. 1 Cortisol responses to insulin and surgery in controls. Adapted
with permission from Plumpton FS, Besser GM [28]
Table 2 Evaluating the utility of the insulin stress test (ITT), glucagon stimulation test (GST) and the short synacthen (corticotropin)
test (SST)
Test Strengths Drawbacks
Insulin tolerance test 1. Very high sensitivity
2. Assessment of ACTH and GH axes
1. Requires experience and medical supervision
2. Labour intensive and time consuming
3. Contraindicated in ischemic heart disease and seizure disorders
4. Hypoglycaemia not always achieved
5. Unpleasant for patients
Glucagon stimulation test 1. Assessment of ACTH and GH axes
2. Can be used in cases where ITT is contra-indicated
1. Nausea in up to 30 % cases




1. Simple and well tolerated
2. Can be used in cases where ITT is contraindicated
3. Reliably excludes clinically significant ACTH
deficiency
1. Does not assess GH axis
2. Unreliable if recent pituitary insult e.g. surgery, apoplexy
3. Theoretical concerns of false negative (pass) rate
(when compared with ITT)
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CRF test
The CRF test has been proposed for the diagnosis of
central adrenal insufficiency and for the distinction be-
tween secondary and tertiary adrenal insufficiency. CRF
(100mcg) is injected intravenously and ACTH and cortisol
measured every 15 min for 90 min. Patients with sec-
ondary adrenal failure have low ACTH levels that fail
to respond to CRF while patients with tertiary (hypo-
thalamic) failure show a prolonged and exaggerated rise
in ACTH levels following CRF. The CRF test is not
widely used to assess the HPA axis due to its unaccept-
ably low sensitivity [40].
Overnight metyrapone test
The overnight metyrapone test assesses the negative
feedback rather than stress related cortisol responses by
utilizing the capacity of metyrapone to inhibit 11β-
hydroxylase, the enzyme responsible for the conversion
of 11-deoxycortisol to cortisol, thereby stimulating
ACTH production and consequently increasing 11-
deoxycortisol levels. While some studies have reported
the metyrapone test to be reliable [41], other authors
raised concerns about its sensitivity and specificity when
using the traditional post-metyrapone 11-deoxycortisol
level >200 nmol/L to define normality [42]. The diagnostic
accuracy of the metyrapone test can be improved by inte-
grating cortisol and ACTH levels with 11-deoxycortisol
measurements [42]. Nevertheless, the assay for 11-
deoxycortisol is a manual assay and is not available in
most laboratories which limits the use of this test par-
ticularly as first line in the assessment of the HPA axis.
Clinical and analytical considerations and caveats
As mentioned above, the SST should be avoided in the
acute phase after a pituitary insult. The 30 min cortisol
response to synacthen is the one which correlates with
the peak cortisol response to hypoglycaemia [39]. The
increment response to either the ITT or SST is less im-
portant than the absolute post-stimulation response
which should be used to define normality.
Defining a normal cortisol response to hypoglycemia
is a matter of contention. The study by Plumpton and
Besser used a fluorimetric (Mattingly) method to mea-
sure serum cortisol and suggested a cut-off value of
580 nmol/L (20 ug/dl) for a normal response [28].
However, it is recognised that the fluorometric method
reported a cortisol concentration that is 20 % higher
than more modern immunoassays. More recent studies
using contemporary cortisol assays redefined the normal
cutoff for cortisol response to the ITT to closer to
500 nmol/L [43, 44] with one recent study suggesting a
peak cortisol level of 414 nmol (14.8 ug/dl) to ITT to be
the minimum acceptable cut-off value for healthy
individuals [45]. In our institution we use a cut-off value
of 500 nmol/L (18 ug/L) to define a normal response to
ITT.
Normative cut-off values for peak cortisol in the GST
are not easy to define but values between 450–500 nmol/l
are appropriate. The GST is associated with an 8 % false
positive (false fail) rate [31] especially when the baseline
cortisol > 400 nmol/l.
Over the years, some endocrinologists have raised
concerns that the SST may not be sensitive enough to
diagnose central hypoadrenalism leading to missed
diagnoses. This was based on studies comparing the
cortisol response to hypoglycaemia with synacthen and
finding that some patients who “failed” the ITT passed
the SST. Unfortunately these studies have many limita-
tions including failure to define normative cut-offs for
ITT and or the SST locally in some studies (see below),
issues regarding poor reproducibility with the ITT and
use of the 60 min rather the 30 min response for the
SST. In addition, it is well known that the ITT errs on
the side of caution and probably overdiagnoses adrenal
insufficiency as some patients do not show a normal
cortisol response to hypoglycaemia but show a healthy
response to major surgery [28].
However, studies looking at the outcome in patients
who pass the SST and therefore were not given gluco-
corticoid replacement are reassuring. In a study of 148
hypothalamic-pituitary patients who passed the SST and
were not treated with hydrocortisone, only 2 patients
subsequently developed adrenal insufficiency, one with
suspected evolving hypopituitarism and one who had a
borderline response [36]. These results confirmed those
of another similar study [37]. Therefore, when time-
related clinical outcome is taken as the “gold standard”
the SST rarely misses clinically significant adrenal insuf-
ficiency provided sufficient time has lapsed between the
pituitary insult and testing [44].
For the SST, the cut-off for normality has been shown
to be assay dependent, and therefore should be deter-
mined in each unit based on responses in healthy controls
[46]. In our institution, we use 500 nmol/l as cutoff for
normal cortisol response, with peak levels of 500–
550 nmol/L interpreted to be safe for the purpose of
withholding routine glucocorticoid therapy but these
patients are prescribed stress dose glucocorticoids in
times of intercurrent illness [36].
Dynamic tests assess ACTH/cortisol reserves rather
than the adequacy of cortisol production from day-to-
day under normal physiological conditions. Hence
patients with partial or borderline responses may not
need day-to-day glucocorticoid replacement as they have
been shown to have normal cortisol production under
unstressed physiological conditions [47]. As a precaution
they should receive sick days glucocorticoid therapy [36].
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Borderline results are often difficult to interpret. The
ITT and the SST are not mutually exclusive and in some
cases both tests can be used to rule in or rule out
adrenal insufficiency when one test alone is borderline
or when the test result does not support the clinical
context. For example a patient with a pituitary tumour
or after pituitary surgery with healthy morning cortisol
level but a sub-optimal cortisol response to hypoglycaemia
and otherwise normal anterior pituitary function is
unlikely to have adrenal insufficiency and therefore a
SST can be useful to verify or vice versa.
Analytical issues are also important when interpreting
the result of a dynamic test. Reproducibility of the ITT
has been shown to be 79 % compared with 88 and 83 %
for the GST and the low dose ACTH stimulation test
respectively [48]. Mean coefficient of variation of cortisol
response to ITT is between 7–10 % and repeat cortisol
values may differ by over 100 nmol/L [49–51]. No test
correctly identifies all cases and borderline results
should be interpreted in the clinical context. Failing to
diagnose ACTH deficiency can have potentially life
threatening consequences leading to adrenal crisis but
over-zealous diagnosis can lead to unnecessary or
over-treatment which has negative consequences for
bone and metabolic health [52, 53].
Normative values should be derived locally as the
cortisol response is both stimulus and assay-dependent.
In one study by Clark et al, the 5th percentile 30 min
cortisol response to the SST ranged from 510 to
626 nmol/L depending on which of four different assays
was used [46]. In a study of 129 patients comparing
ITT, GST and low dose synacthen testing Simsek et al
would have to treat 75, 65 and 40 % of the patients with
glucocorticoids if they used the same cut-off of
500 mmol/L to diagnose central hypoadrenalism using
these tests [48]. Furthermore, in clinical practice, labora-
tories measure total rather than the biologically active
free cortisol. In situations where significant alterations
in binding proteins exist, total cortisol measurement
can be grossly misleading leading to misdiagnosis. For
example septic patients have low levels of CBG and
albumin hence their total cortisol measurement is much
lower relative to their free cortisol measured by equilib-
rium dialysis [54] while patients taken estrogen will
have an elevation in their total cortisol relative to free
cortisol due to increased levels of binding proteins [55].
Conclusion
The choice of test used to interrogate the HPA axis
should be individualised for each patient and the results
interpreted within clinical context and with understan-
ding of potential pitfalls of the test used. An alternative
test should be performed if the result is borderline and
clinical suspicion is high. Clinical vigilance is required
and patients should be made aware of the symptoms
and signs of adrenal insufficiency so that assessment
can be repeated if necessary. The results should be
interpreted rationally and those with apparent border-
line normal/abnormal results or values suggestive of
partial ACTH deficiency could be treated with short
courses of stress dose of glucocorticoids during incur-
rent illness only.
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